Sign up Australia
Proactive Investors - Run By Investors For Investors

Admedus using capital raised to advance product development and share price growth

Admedus Ltd (ASX:AHZ) chief executive Wayne Paterson updates Proactive Investors on product development, a major agreement, key executive appointments, and strategic financing decisions.

The global medical technologies company recently completed a $6 million capital raise. "On what is our strategy to move that share price; I realised that if we developed the portfolio, the share price would move much more quickly, and would certainly flush out any dilution impact of a small cap raise... I think [we're] probably going to bring forward the progress of the company by a couple of years," says Paterson.

Admedus has recently appointed key staff members with big pharma backgrounds. Paterson comments, "we've got very good assets, we've got a clear sense of strategy, we're growing the business dramatically, and we are now getting those folks; both in the field force [and in] key positions."

The drug development Immunotherapies Division has attracted a financing partner which will hold a majority stake moving forwards. Paterson explains that shareholders will "get to participate in the upside without putting any more money into that project, so it's a very good outcome."  

Meanwhile, development of the company’s flagship portfolio of 3D moulded surgical solutions continues. "If you imagine Admedus three years from now it will be the only company in the world, as far as I'm aware, that can make 3D surgical collagen solutions," says Paterson.

 
Meet Tower Resources PLC, Arc Minerals Limited, Carbon Tracker, Tekcapital PLC and Serinus Energy at our event, London , 31 May 2018. Register here »
View full AHZ profile View Profile

Admedus Ltd Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use